Functional interactions between P-glycoprotein and CYP3A in drug metabolism.

Abstract:

:The interaction between drug-metabolising enzymes and active transporters is an emerging concept in pharmacokinetics. In the gut mucosa, P-glycoprotein and cytochrome P450 (CYP)3A functionally interact in three ways: i) drugs are repeatedly taken up and pumped out of the enterocytes by P-glycoprotein, thus increasing the probability of drugs being metabolised; ii) P-glycoprotein keeps intracellular drug concentrations within the linear range of the metabolising capacity of CYP3A; and iii) P-glycoprotein transports drug metabolites formed in the mucosa back into the gut lumen. In comparison with the gut mucosa, in hepatocytes the spatial sequence of CYP3A and P-glycoprotein is reversed, resulting in different effects when the activity of one or both are changed. CYP3A and P-glycoprotein are both regulated by nuclear receptors such as the pregnane X receptor (PXR). There is significant genetic variability of CYP3A, P-glycoprotein and PXR and their expression and activity is dependent on coadministered drugs, herbs, food, age, hormonal status and disease. Future pharmacogenomic and pharmacokinetic studies will have to take all three components into account to allow for valid conclusions.

authors

Christians U,Schmitz V,Haschke M

doi

10.1517/17425255.1.4.641

subject

Has Abstract

pub_date

2005-12-01 00:00:00

pages

641-54

issue

4

eissn

1742-5255

issn

1744-7607

journal_volume

1

pub_type

杂志文章,评审
  • Bioactivation of herbal constituents: simple alerts in the complex system.

    abstract:INTRODUCTION:The elucidation of the toxicological mechanisms of herbal medicines is becoming more and more important with the increasing application of herbal medicines, for treatment of various diseases and the promotion of health. Furthermore, it is widely recognized that as herbal components undergo bioactivation, t...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.586335

    authors: Fang ZZ,Zhang YY,Wang XL,Cao YF,Huo H,Yang L

    更新日期:2011-08-01 00:00:00

  • Pharmacokinetics considerations for gout treatments.

    abstract:INTRODUCTION:Patients with gout often have comorbid conditions such as renal failure, cardiovascular disease and metabolic syndrome. The presence and required treatment of these conditions can make the treatment of gout challenging. Knowledge of the pharmacokinetics of the available drugs for the management of gout is ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2014.915027

    authors: Richette P,Frazier A,Bardin T

    更新日期:2014-07-01 00:00:00

  • Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.

    abstract:INTRODUCTION:Chronic constipation is a frequent condition often treated pharmacologically. The laxatives available belong to very different pharmacologic groups. AREAS COVERED:This is a short but comprehensive review of the pharmacology, efficacy and safety of currently available laxatives for chronic constipation. Pe...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2013.773972

    authors: Müller-Lissner S

    更新日期:2013-04-01 00:00:00

  • Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.

    abstract:INTRODUCTION:Treatments for hepatitis C virus (HCV) infection have advanced rapidly in the last decade. Pegylated interferon alpha 2a (PEG-IFN alpha 2a) alone, in combination with ribavirin and with or without direct acting antivirals (DAAs) is modestly effective in the treatment of chronic HCV infection. Areas covered...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2018.1421173

    authors: Maughan A,Ogbuagu O

    更新日期:2018-02-01 00:00:00

  • Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity.

    abstract::Extensive growth in the field of molecular biology in recent decades has led to the development of new and powerful experimental and computational tools that enable the analysis of complex biological responses to chemical exposure on both a functional and structural genetic level. The ability to profile global respons...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.4.11.1379

    authors: Harrill AH,Rusyn I

    更新日期:2008-11-01 00:00:00

  • Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.

    abstract:INTRODUCTION:Telaprevir is one of the first direct-acting antiviral drugs approved for the treatment of the hepatitis C virus (HCV) genotype 1. Following its approval in 2011, new data regarding the pharmacokinetics and pharmacodynamics were reported, leading to important clinical applications. AREAS COVERED:This arti...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1049532

    authors: Rivero-Juarez A,Camacho A,Rivero A

    更新日期:2015-07-01 00:00:00

  • Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Type 2 diabetes often involves derangements in lipid levels in addition to insulin resistance and diminishing insulin secretion. Colesevelam hydrochloride, a bile acid sequestrant (BAS), is approved for adjunctive therapy to diet and exercise for glycemic control in type 2 diabetes. In clinical studies in ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.672973

    authors: Younk LM,Davis SN

    更新日期:2012-04-01 00:00:00

  • Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.

    abstract::The onset, intensity and duration of therapeutic response to a compound depend on the intrinsic pharmacological activity of the drug and pharmacokinetic factors related to its absorption, distribution, metabolism and elimination that are inherent to the biological system. The process of drug transfer from the site of ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425225.3.4.469

    authors: Hurst S,Loi CM,Brodfuehrer J,El-Kattan A

    更新日期:2007-08-01 00:00:00

  • Bioaccessibility of polycyclic aromatic hydrocarbons: relevance to toxicity and carcinogenesis.

    abstract:INTRODUCTION:Bioaccessibility is a growing area of research in the field of risk assessment. As polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants, they are the toxicants of focus to establish cancer risks in humans. Orally ingested PAHs also cause toxicity and even affect the pharmacokinet...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2013.823157

    authors: Harris KL,Banks LD,Mantey JA,Huderson AC,Ramesh A

    更新日期:2013-11-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation.

    abstract:INTRODUCTION:The availability of non-vitamin K antagonist oral anti-coagulants alongside vitamin K antagonists has offered a variety of options for anti-coagulation, but has also necessitated a good understanding of the pharmacological properties of each of these drugs prior to their use, to maximise the therapeutic be...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2019.1604686

    authors: Fawzy AM,Lip GYH

    更新日期:2019-05-01 00:00:00

  • Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.

    abstract:INTRODUCTION:The pharmacokinetic properties of anti-infective drugs are a determinant part of treatment success. Pathogen replication is inhibited if adequate drug levels are achieved in target sites, whereas excessive drug concentrations linked to toxicity are to be avoided. Anti-infective distribution can be predicte...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1037278

    authors: Moss DM,Marzolini C,Rajoli RK,Siccardi M

    更新日期:2015-01-01 00:00:00

  • What is the role of pharmacogenetics in clinical psychiatry?

    abstract::Psychiatric disorders are a leading cause of disability worldwide and despite significant pharmacologic advances, often remain difficult to diagnose correctly and treat fully. Factors which contribute to these difficulties include imprecise understanding of etiology, syndromal nature of many disorders and overlap in d...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 社论

    doi:10.1517/17425255.2013.733696

    authors: Lombard J,Doraiswamy PM

    更新日期:2013-01-01 00:00:00

  • Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.

    abstract:INTRODUCTION:Lenalidomide is an oral immunomodulatory drug, which was recently introduced for the treatment of multiple myeloma (MM). It has been used for the treatment of newly diagnosed and relapsed MM patients, as both maintenance and preventive therapy. Available data show a progression-free survival and overall su...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.712685

    authors: Bringhen S,Gay F,Pautasso C,Cerrato C,Boccadoro M,Palumbo A

    更新日期:2012-09-01 00:00:00

  • An update on chemotherapy and tumor gene expression profiles in breast cancer.

    abstract:INTRODUCTION:Various trials have attempted to develop gene expression profiles (GEPs) that may provide a better predictor of clinical outcome over traditional clinicopathological criteria. AREAS COVERED:The review focuses on two main areas: trials examining chemotherapy-induced GEP changes pre- and post-treatment, and...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.694867

    authors: Tan SH,Lee SC

    更新日期:2012-09-01 00:00:00

  • Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs.

    abstract::Changes in mammalian diets alter the hepatic expression of CYP drug-metabolising enzymes and endobiotic oxidases. Thus, dietary constituents may significantly influence the duration of action of chemicals in tissues. Recent improvements in the mechanistic information on the regulation of constitutive and inducible exp...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.3.2.185

    authors: Murray M

    更新日期:2007-04-01 00:00:00

  • Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

    abstract:INTRODUCTION:Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties. AREAS COVERED:This review covers material searched and ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1056732

    authors: Calcagno A,D'Avolio A,Bonora S

    更新日期:2015-07-01 00:00:00

  • The influence of gut microbiota on drug metabolism and toxicity.

    abstract:INTRODUCTION:Gut microbiota plays critical roles in drug metabolism. The variation of gut microbiota contributes to the interindividual differences toward drug therapy including drug-induced toxicity and efficacy. Accordingly, the investigation and elucidation of gut microbial impacts on drug metabolism and toxicity wi...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2016.1121234

    authors: Li H,He J,Jia W

    更新日期:2016-01-01 00:00:00

  • Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures.

    abstract:INTRODUCTION:The goal of pharmacologic therapy with antiepileptic drugs (AEDs) is to reduce the frequency of seizures and achieve a seizure-free state with minimal side effects. However 30% of patients treated with available AEDs continue to experience uncontrolled seizures. There is still need for new AEDs with enhanc...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1360278

    authors: de Biase S,Valente M,Gigli GL,Merlino G

    更新日期:2017-09-01 00:00:00

  • Ethnic differences in drug metabolism and toxicity from chemotherapy.

    abstract::There is wide inter-individual variability in the pharmacokinetics, pharmacodynamics and tolerance of anticancer drugs. Recent evidence suggests that there is even greater variability between individuals of different ethnicity. Allelic variants of genes encoding drug metabolising enzymes are expressed with different i...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425250902800153

    authors: Phan VH,Moore MM,McLachlan AJ,Piquette-Miller M,Xu H,Clarke SJ

    更新日期:2009-03-01 00:00:00

  • Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.

    abstract::Three first-line antituberculosis drugs, isoniazid, rifampicin and pyrazinamide, may induce liver injury, especially isoniazid. This antituberculosis drug-induced liver injury ranges from a mild to severe form, and the associated mortality cases are not rare. The major drug-metabolizing enzyme of isoniazid is N-acetyl...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.3.1.1

    authors: Huang YS

    更新日期:2007-02-01 00:00:00

  • Telmisartan in the treatment of hypertension.

    abstract:BACKGROUND:Telmisartan is an orally active angiotensin II receptor antagonist prescribed once daily. OBJECTIVE:To evaluate the efficacy of telmisartan on blood pressure control, and on other end points, when given as monotherapy or in combination. METHODS:Review of published literature. RESULTS:Telmisartan produces ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.4.4.485

    authors: Rosario BH,Hendra TJ

    更新日期:2008-04-01 00:00:00

  • Tools for predicting the PK/PD of therapeutic proteins.

    abstract:INTRODUCTION:Assessments of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics are an integral part in the development of novel therapeutic agents. Compared with traditional small molecule drugs, therapeutic proteins possess many distinct PK/PD features that necessitate the application of modified or separate ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1041917

    authors: Diao L,Meibohm B

    更新日期:2015-07-01 00:00:00

  • Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.

    abstract:INTRODUCTION:The fixed-dose combination of three direct-acting antivirals (DAA), namely sofosbuvir, velpatasvir and voxilaprevir is the first pangenotypic, single tablet regimen developed for the treatment of HCV infection. Areas covered: The pharmacokinetics, pharmacodynamics, efficacy and safety of the co-formulation...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1359254

    authors: Soriano V,Benítez-Gutiérrez L,Arias A,Carrasco I,Barreiro P,Peña JM,de Mendoza C

    更新日期:2017-09-01 00:00:00

  • The use of accelerator mass spectrometry to obtain early human ADME/PK data.

    abstract::There is an increasing recognition within the pharmaceutical industry of the importance of the ADME studies in drug registration. Consequently, there has been a drive in recent times to conduct the ADME studies as early as possible in the development programme. There are, however, regulatory barriers, particularly in ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.1.1.23

    authors: Lappin G,Garner RC

    更新日期:2005-06-01 00:00:00

  • Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.

    abstract::Introduction: Overactive bladder (OAB) has a heterogeneous presentation that varies between individuals and by gender. Treatment with antimuscarinic medications is standard first line pharmacotherapy for most patients with OAB. However, gender specific differences in the pharmacokinetics and pharmacodynamics of antimu...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2020.1714591

    authors: Hartigan SM,Dmochowski RR

    更新日期:2020-02-01 00:00:00

  • Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.

    abstract:INTRODUCTION:The fixed-dose combination therapy of sofosbuvir (SOF) plus velpatasvir (VEL) is the first pangenotypic, direct-acting antiviral (DAA), single-treatment regimen (STR) for the treatment of hepatitis C virus (HCV) infection to be commercialized. It is approved for the treatment of HCV genotypes 1, 2, 3, 4, 5...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1292253

    authors: Brieva T,Rivero A,Rivero-Juarez A

    更新日期:2017-04-01 00:00:00

  • Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.

    abstract:OBJECTIVES:A medical need remains for a once-daily insulin with 24-h basal coverage in all patients. We characterize the steady-state (SS) pharmacokinetic/pharmacodynamic properties of insulin degludec (IDeg) versus insulin glargine (IGlar). RESEARCH DESIGN AND METHODS:In this controlled, single-center study, 66 type ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/17425255.2015.1058779

    authors: Heise T,Hövelmann U,Nosek L,Hermanski L,Bøttcher SG,Haahr H

    更新日期:2015-01-01 00:00:00

  • Mechanistic biomarkers for cytotoxic acute kidney injury.

    abstract::Acute kidney injury is a common condition and is associated with a high mortality rate. It has been recognised that routinely used measures of renal function, such as levels of blood urea nitrogen and serum creatinine, increase significantly only after substantial kidney injury occurs and then with a time delay. Insen...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2.5.697

    authors: Vaidya VS,Bonventre JV

    更新日期:2006-10-01 00:00:00

  • Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.

    abstract:INTRODUCTION:Multiple myeloma (MM) patients who relapse, or become refractory to currently available novel agents, have limited treatment options with poor outcomes. The introductions of the newer proteasome inhibitor carfilzomib and the immunomodulatory agent pomalidomide have provided new treatment strategies within ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2013.827169

    authors: Gay F,Mina R,Troia R,Bringhen S

    更新日期:2013-11-01 00:00:00

  • Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.

    abstract:INTRODUCTION:Cardiovascular disease is still the leading cause of death worldwide. There are many environmental and genetic factors that play a role in the development of cardiovascular disease. The treatment of cardiovascular disease is beginning to move in the direction of personalized medicine by using biomarkers fr...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1363887

    authors: Berinstein E,Levy A

    更新日期:2017-09-01 00:00:00